We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Industry Insights

Less Time Managing Inventory, More Time at the Bench? Yes Please
Industry Insight

Lab efficiency is critical to speeding up development processes, yet many researchers find they spend more time managing consumables data than working at the bench. Lab informatics is one solution to this problem.

Read More

Advancing Skin Cancer Pathology With AI Image Analysis
Industry Insight

Image analysis can be a painstaking process for skin cancer pathologists. New technologies are needed to relieve the pressure. We spoke with Nathan Buchbinder, Proscia’s CPO, to find out more about their DermAI software and how it could be part of the solution.

Read More

Advancing ALS Research With Omics Analysis Technology
Industry Insight

Clinical trials produce a massive amount of medically relevant and highly sensitive data. Leveraging such data could make a difference to efforts to create more personalized, effective medicines. We talked to Medidata’s Sheila Diamond to find out more.

Read More

A New System for DNA/RNA Delivery in Cancer Therapeutics
Industry Insight

Cancer immunotherapies and viral vaccines that are nucleic acid-based can be challenging to formulate and require highly specific delivery systems. Commonly adopted delivery systems, such as lipid nanoparticles and viral vectors, can have limitations, therefore alternative approaches are being developed. Technology Networks recently spoke with Nigel Theobald, CEO and Founder of N4 Pharma, to learn more about nanoparticle drug delivery, the Nuvec® platform and its progress towards clinical trials.

Read More

Harnessing the Immune System for Early Cancer Detection
Industry Insight

With the number of new cancer cases worldwide per year predicted to rise to 23.6 million by 2030, it seems as pertinent as ever that the disease is stopped early in its tracks. We spoke with Mike Fisher, Ph.D., Commercial Director of Oncimmune, to find out more about a trial utilizing a simple blood test for early detection of lung cancer.

Read More

Removing the Barriers to Broad Adoption of NGS in Diagnostics
Industry Insight

What barriers still exist to the full implementation of next-generation sequencing (NGS) in the diagnostics space, and how can we remove them? Technology Networks recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific, to learn more.

Read More

The Power of Positrons
Industry Insight

Over the last five to ten years, multi-modal imaging has become established as a significant component of a preclinical researcher’s analytical toolbox. Here, we highlight perhaps the most used and certainly the most sensitive and quantitative of these imaging modalities, the combination of positron emission tomography (PET) with X-ray computed tomography (CT), or PET/CT.

Read More

Drug Candidate for Lung Cancer Receives FDA Fast Track Designation
Industry Insight

Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex, a lead drug candidate that treats non-small cell lung cancer, and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.

Read More

Leveraging AI To Find the “Right” Clinical Trial
Industry Insight

Less than 5% of adult cancer patients enroll in clinical trials even though it is estimated that a large percentage (70% of Americans) are very willing to take part in a clinical study. So, why is there such a large discrepancy in the number of actual participants versus those willing to, but not actually participating?

Read More

Detecting the Presence of Cancer in Patients’ Breath
Industry Insight

Thermo Fisher Scientific and Owlstone Medical have recently entered a collaboration, with the aim of advancing breath diagnostics for the early diagnosis of cancer and other diseases. Dr Max Allsworth, Chief Science Officer, Owlstone Medical, and Dominic Roberts, Product Marketing Manager, Orbitrap GC-MS, Thermo Fisher Scientific tell us more about the collaboration and the advantages that breath biopsies can bring to disease detection.

Read More

 
Advertisement